

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA PIONEER PHARMA HOLDINGS LIMITED**

**中国先锋医药控股有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 01345)**

### **INCORPORATION OF A SUBSIDIARY**

This announcement is made by China Pioneer Pharma Holdings Limited (the “**Company**”) on voluntary basis.

The board of directors of the Company (and together with its subsidiaries, the “**Group**”) is pleased to announce that the Company’s subsidiary, Pioneer Pharma (Hong Kong) Company Limited, has incorporated a wholly-owned subsidiary, namely, Haikou Pioneer Pharma Leasing Company Limited (“**Haikou Pioneer Pharma**”) in the People’s Republic of China.

Particulars of Haikou Pioneer Pharma are as follows:

Registered Name:	海口先锋医药租赁有限公司
Translated Name:	Haikou Pioneer Pharma Leasing Company Limited
Date of Incorporation:	18 December 2013
Place of Incorporation:	Hi-Tech Industrial Development Zone in Haikou City, Hainan Province, the People’s Republic of China
Legal Representative:	Mr. Li Xinzhou
Principal Activities:	Medical devices, equipment and ancillary tools and accessories leasing; consulting service of international brand medical devices and equipment; joint venture or cooperation with domestic enterprises engaged in hospital investment, asset management and consulting

Registered Capital: RMB290,000,000

Date of Completion of  
Capital Verification: 13 January 2014

The incorporation of Haikou Pioneer Pharma was in accordance with the Group's plan to expand its business operations and to enhance its position in the rapidly growing Chinese healthcare market.

The incorporation of Haikou Pioneer Pharma was funded by the proceeds received from the initial public offering of the Company's shares consummated on 5 November 2013, used for, among other things, purchasing of imported medical devices from overseas suppliers to meet the increasing demand for our products and establishing training and conference centers in select regions (such as Shanghai), which is in line with the disclosure in the prospectus issued by the Company dated 24 October 2013, and the aforesaid incorporation is not expected to have any material impact on the Group's operating results for the financial year ended 31 December 2013.

None of the directors or substantial shareholders of the Company has any interest, direct or indirect, in the aforesaid incorporation (other than their shareholdings in the Company).

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**China Pioneer Pharma Holdings Limited**  
**Li Xinzhou**  
*Chairman*

Hong Kong, 13 January 2014

*As at the date of this announcement, the directors of the Company are Mr. LI Xinzhou, Mr. ZHU Mengjun as executive Directors, Mr. LU Yuan, Mr. WU Mijia and Mr. ZHANG Wenbin as non-executive Directors and Mr. XU Zhonghai, Mr. LAI Chanshu and Mr. WONG Chi Hung, Stanley as independent non-executive Directors.*